VRP Verona Pharma Plc

 
TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
                            Grant of Share Options 
 
30 January 2015, Cardiff - Verona Pharma plc (AIM: VRP) announces that the 
Board has on 29 January 2015 granted options over 32,600,000 ordinary shares 
("Options") in the Company to certain of its executive directors and employees, 
in accordance with the terms of the Company's share option plans. Half of the 
Options will vest on 29 January 2017 and the other half on 29 January 2018. 
 
Of the Options granted, 17,000,000 are to the following executive directors: 
 
Director                  No. of Options granted   Exercise Price of 
                                                   Options 
 
Jan-Anders Karlsson, CEO  15,000,000               2.5 pence 
 
Biresh Roy, CFO           2,000,000                2.5 pence 
 
Jan-Anders Karlsson's total beneficial interest in the Company remains 
1,709,091 ordinary shares, representing 0.17% of the Company's issued share 
capital. Following this grant, Dr. Karlsson holds options over 28,000,000 
ordinary shares, representing 2.77% of the Company's issued share capital, with 
a range of exercise prices between 2.5 and 15 pence per option. 
 
Following this grant, Biresh Roy holds options over 8,000,000 ordinary shares, 
representing 0.79% of the Company's issued share capital, with a range of 
exercise prices between 2.2 and 2.5 pence per option. 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                       Tel: +44 (0) 20 3283 4200 
Jan-Anders Karlsson, CEO 
 
N+1 Singer                              Tel: +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as COPD, asthma 
and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class 
drug currently in Phase II trials as a nebulised treatment for acute 
exacerbations of COPD in the hospital setting. The drug is a 
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both 
bronchodilator and anti-inflammatory effects, which are essential to the 
improvement of patients with COPD and asthma. Verona Pharma is also building a 
broader franchise around RPL554 to maximise its value, both to patients and to 
investors. This includes the very significant markets for COPD and asthma 
maintenance therapy. The Company is also exploring the potential of the drug in 
different diseases, such as cystic fibrosis, where it is in pre-clinical 
testing. 
 
 
 
 
END 
 

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024